Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning

Экономическая оценка факторных исследований: анализ «затраты—полезность» в факторном исследовании AFORRD «Аторвастатин в факторной комбинации с омега-3 для снижения риска при сахарном диабете» с дизайном 2 × 2 × 2, изучающем аторвастатин, рыбий жир омега-3 и планирование действий
Rury R. Holman, Andrew A. Farmer, Alastair McIntosh Gray, Helen Dakin
2020-08-18

2 × 2 × 2 factorial trialatorvastatincost-effectiveness acceptability curvescost-utility analysisomega-3 fish oil
OBJECTIVES: We applied principles for conducting economic evaluations of factorial trials to a trial-based economic evaluation of a cluster-randomized 2 × 2 × 2 factorial trial. We assessed the cost-effectiveness of atorvastatin, omega-3 fish oil, and an action-planning leaflet, alone and in combination, from a UK National Health Service perspective. METHODS: The Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes (AFORRD) Trial randomized 800 patients with type 2 diabetes to atorvastatin, omega-3, or their respective placebos and randomized general practices to receive a leaflet-based action-planning intervention designed to improve compliance or standard care. The trial was conducted at 59 UK general practices. Sixteen-week outcomes for each trial participant were extrapolated for 70 years using the United Kingdom Prospective Diabetes Study Outcomes Model v2.01. We analyzed the trial as a 2 × 2 factorial trial (ignoring interactions between action-planning leaflet and medication), as a 2 × 2 × 2 factorial trial (considering all interactions), and ignoring all interactions. RESULTS: We observed several qualitative interactions for costs and quality-adjusted life-years (QALYs) that changed treatment rankings. However, different approaches to analyzing the factorial design did not change the conclusions. There was a ≥99% chance that atorvastatin is cost-effective and omega-3 is not, at a £20 000/QALY threshold. CONCLUSIONS: Atorvastatin monotherapy was the most cost-effective combination of the 3 trial interventions at a £20 000/QALY threshold. Omega-3 fish oil was not cost-effective, while there was insufficient evidence to draw firm conclusions about action planning. Recently-developed methods for analyzing factorial trials and combining parameter and sampling uncertainty were extended to estimate cost-effectiveness acceptability curves within a 2x2x2 factorial design with model-based extrapolation.
1
A trial-based economic evaluation assessed atorvastatin, omega-3 fish oil, and an action-planning leaflet individually and in combination from the UK NHS perspective.
2
At a £20,000/QALY threshold, atorvastatin had at least a 99% probability of being cost-effective, whereas omega-3 fish oil was not cost-effective.
3
Atorvastatin monotherapy was the most cost-effective intervention combination; evidence was insufficient to determine whether action planning was cost-effective.
4
Qualitative interactions affected costs and QALYs and changed treatment rankings, but alternative analyses of the factorial design produced the same overall conclusions.
5
Sixteen-week trial outcomes from 800 patients across 59 UK general practices were extrapolated over 70 years using the UKPDS Outcomes Model v2.01.
6
The study extended factorial-trial methods for combining parameter and sampling uncertainty to estimate cost-effectiveness acceptability curves with model-based extrapolation.

The 2 × 2 × 2 factorial trial interventions in patients with type 2 diabetes: atorvastatin, omega-3 fish oil, and a leaflet-based action-planning intervention

The cost-effectiveness of the interventions alone and in combination, including their effects on costs, quality-adjusted life-years, treatment rankings, and interactions

Publication Details
Publication Date
2020-08-18
Journal
Publisher
ISSN
Cited by
5
Access Type
Author Information
Authors
Rury R. Holman
Andrew A. Farmer
Alastair McIntosh Gray
Helen Dakin
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%